Currently, B-cell maturation antigen (BCMA) targeting Abecama® for the treatment of refractory multiple myeloma and CarvyktiTM for refractory multiple myeloma and CD19 targeting Breyanzi® for large B-cell lymphoma, KymriahTM for refractory diffuse large B-cell lymphoma, TecartusTM for refractory mantle cell lymphoma, and YescartaTM for high-grade, primary mediastinal and diffuse large B-cell lymphomas have received approval from FDA for cancer immunotherapy. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.